Persistence, Compliance And Bisphosphonate Switching In Patients With Multiple Myeloma (MM) In Germany

OBJECTIVES: This retrospective observational analysis aimed to estimate persistence, compliance and switch patterns in MM patients newly treated with bispho-sphonates (BPs) approved in Germany for the prevention of SREs. METHODS: This was a retrospective analysis of German health insurance claims da...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A463
Main Authors: Intorcia, M, Ansorge, S, Giannopoulou, C, Hohmann, D
Format: Article
Language:English
Subjects:
Bisphosphonates
Compliance
First year
Health insurance
Hypercalcemia
Ibandronic acid
Intravenous administration
Kidney diseases
Medical treatment
Multiple myeloma
Myeloma
Newly diagnosed
Pamidronic acid
Patients
Prescription drugs
Zoledronic acid
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: This retrospective observational analysis aimed to estimate persistence, compliance and switch patterns in MM patients newly treated with bispho-sphonates (BPs) approved in Germany for the prevention of SREs. METHODS: This was a retrospective analysis of German health insurance claims data (including ~4 million patients). The study included newly diagnosed MM patients aged ≥18 with no prior hypercalcemia, undergoing BP treatment for the first time. Descriptive analyses to estimate persistence, compliance and switch rate among first line intravenous BP treatments were performed. Persistence was defined as continuous prescriptions with
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.367